Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 140 participants.
Also called NCT05920889
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 140 participants
- Registry
-
NCT05920889
-
- Other papers using this trial's data
- Glucagon-like peptide-1 receptor agonist in large vessel occlusion treated by reperfusion therapy-a phase 2 randomized trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China, Hong Kong SAR China
- Registry status
- Completed
Technical summary
Registry record NCT05920889. Randomized; no masking; primary purpose treatment. Start 2023-08-01 (actual); primary completion 2024-10-25 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies
- Acronym
- GALLOP
- Condition
- Stroke
- Condition
- Stroke, Acute
- Condition
- Stroke, Ischemic
- Condition
- Brain Diseases
- Intervention (Drug)
- Semaglutide
- Lead sponsor
- Chinese University of Hong Kong
- Collaborator
- Linyi People's Hospital
Record details
- Record id
cardio:ct-nct05920889- Content hash
a1b44c1cf300841fbe973701f809187092d9fdca139e9c42aea03da615cc3788